口服避孕药市场依产品类型、剂型、剂量强度、品牌及通路划分－2025-2032年全球预测

预计到 2032 年，口服避孕药市场规模将达到 317.7 亿美元，复合年增长率为 7.08%。

主要市场统计数据
基准年 2024	183.6亿美元
预计年份：2025年	196.6亿美元
预测年份：2032年	317.7亿美元
复合年增长率 (%)	7.08%

简要概述了目前口服避孕药的现状，重点阐述了影响相关人员决策的临床、监管和获取途径等方面的动态。

口服避孕药仍然是全球生殖健康策略的基石，其在计划生育、临床护理和公共卫生政策中的作用也在不断演变。医疗服务提供者、付款方和生产商所处的环境受到监管重点变化、远距远端医疗服务扩展以及患者对安全性、便利性和成本透明度的期望不断提高的影响。因此，对于那些必须在临床疗效与供应链和商业性现实之间取得平衡的利害关係人相关人员，了解影响药物配製、依从性和可及性的动态至关重要。

数位医疗的扩张、监管格局的调整以及药物配方的演变，正在如何再形成口服避孕药市场的获取途径、用药行为和医疗服务提供者的策略？

口服避孕药市场正经历一场变革性的转变，这场变革正在改变产品的研发、配製、分销以及使用者认知。数位医疗的进步加速了远端医疗咨询和线上药局的发展，使配製药物更加便捷，但也带来了新的合规性和检验的挑战。与此同时，政策倡议——例如某些地区的非处方药销售以及另一些地区扩大药剂师的配製权限——正在改变传统的准入把关者，并迫使製造商重新思考包装、标籤和患者支持服务。

分析近期美国关税如何促使口服避孕药生态系进行供应链重组、来源多元化以及筹资策略调整。

美国近期推出的贸易执法措施对口服避孕药供应链的多个环节产生了累积影响。更高的进口关税和对上游供应商更严格的审查可能会改变原料药采购和成品药生产的成本核算，促使生产商重新评估筹资策略、生产布局和库存政策。因此，各公司正在考虑近岸外包、双重采购和签订长期供应商协议，以降低关税波动带来的风险，并确保供应的连续性。

将产品类型、配方差异、剂量策略、品牌定位和分销管道与竞争和业务重点联繫起来的详细细分资讯。

关键的市场区隔考量揭示了产品属性、配方、给药策略、品牌定位和通路结构如何相互作用，从而决定竞争机会和风险。按产品类型划分，口服避孕药和仅含孕激素的避孕药之间的市场差异导致了不同的药物组合模式、耐受性特征和目标患者群体，这些差异会影响行销、医学教育和配方设计。按剂型划分，双相、单相和三相製剂之间的差异会影响出血模式、週期控制预期以及临床医生和患者的教育讯息。

针对美洲、欧洲、中东和非洲以及亚太地区的区域战略考量，将决定监管重点、分销管道和生产​​选择。

区域动态为在不同地理丛集运作的相关人员创造了不同的策略要务。在美洲，法律规范、支付方构成和远端医疗普及率影响着零售药局、医院采购和线上销售之间的平衡，进而影响着特定的市场进入模式和报销考量。相较之下，欧洲、中东和非洲在监管要求和医疗基础设施方面存在显着差异，因此需要采取适应性强的许可策略、差异化的临床证据包装以及经销伙伴，以反映当地的采购规范和公共采购週期。

竞争情报揭示了配方创新、供应韧性、策略伙伴关係和生命週期管理如何驱动口服避孕药领域的领先地位。

口服避孕药领域的企业竞争动态取决于配方创新、供应链韧性、商业性可行性以及向临床医生和支付方展现差异化价值的能力。典型的策略措施包括投资以病人为中心的资讯和依从性服务、确保关键中间体的长期供应协议，以及优先利用监管管道加速市场进入。此外，生命週期管理策略，例如配方改进、包装重新设计和适应症扩展，也常被用于延长产品生命週期并维繫配方研发人员的忠诚度。

为行业领导者提供可操作的策略重点，以协调证据生成、采购韧性、数位化参与和相关人员倡导，从而实现持续的市场优势。

为了保持竞争优势，产业领导者应采取多管齐下的策略，协调临床证据的产生、供应链的弹性和通路商业化。首先，将可靠的真实世界依从性测试和上市后监测纳入产品系列，有助于加强与支付方的谈判，并为临床通讯传递提供依据。其次，透过合格的双重采购和选择性近岸外包，实现原料药和成品生产的多元化，可以在保持成本竞争力的同时，降低受贸易政策变化和物流中断的影响。

一个严谨的混合方法研究框架，结合了相关人员访谈、监管和临床文献整合以及交叉检验的情境分析，以得出可操作的结论。

本分析所依据的研究结合了定性和定量方法，旨在验证趋势、整合不同观点，并为决策者提供切实可行的建议。主要研究包括对临床医生、采购负责人、药房主任和行业高管进行结构化检验，以获取有关配药行为、筹资策略和分销挑战的第一手资料。次要研究则利用监管文件、临床指南更新、政策公告和开放原始码文献，揭示了药物取得和製剂偏好的变化。

将监管变革、供应链韧性、配方创新和以患者为中心的交付方式有效整合，是该领域未来成功的核心驱动力。

摘要：口服避孕药市场正处于曲折点，不断变化的监管环境、数位化管道和供应链动态正在共同重塑产品的研发、供应和使用方式。积极主动地将临床证据的生成与适应性筹资策略和管道专属的商业化相结合的相关人员，将更有能力满足不断变化的患者需求并降低风险。过渡性政策措施和贸易发展凸显了灵活采购和长期供应商关係的重要性，而製剂差异化和病患支援服务则为企业提供了明确的竞争优势途径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 哺乳期和产后母亲使用仅含孕激素的口服避孕药的比例增加
• 人们越来越倾向于选择低剂量复方口服避孕药，以最大限度地减少副作用并提高用药偏好。
• 市场对具有临床验证的健康益处（除避孕功效外）的口服避孕药的需求激增
• 扩大线上避孕药配製和家庭配送远端医疗服务的整合
• 无激素、短週期（24/4）和长週期避孕药越来越受欢迎
• 数位生育追踪应用程式的出现，结合个人化口服避孕药用于週期管理。
• 随着主要品牌口服避孕药专利到期，非专利药的市场渗透率不断提高。
• 消费者偏好转向环保包装与永续采购

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的口服避孕药市场

• 复方口服避孕药
• 仅含黄体素的避孕药

第九章 依剂型分類的口服避孕药市场

• 双相
• 单相
• 三相

第十章 以剂量强度分類的口服避孕药市场

• 高剂量
• 低剂量

第十一章 口服避孕药品牌市场

• 品牌
• 非专利的

第十二章 口服避孕药市场（依通路划分）

• 医院药房
  • 私立医院
  • 公立医院
• 线上平台
• 零售药房

第十三章 各地区口服避孕药市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 口服避孕药市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国口服避孕药市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Gedeon Richter Plc
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sandoz International GmbH

The Oral Contraceptive Pills Market is projected to grow by USD 31.77 billion at a CAGR of 7.08% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 18.36 billion
Estimated Year [2025]	USD 19.66 billion
Forecast Year [2032]	USD 31.77 billion
CAGR (%)	7.08%

A succinct orienting overview of the contemporary oral contraceptive pills landscape highlighting clinical, regulatory, and access dynamics shaping stakeholder decisions

Oral contraceptive pills remain a cornerstone of reproductive health strategies globally, and their role in family planning, clinical care, and public health policy continues to evolve. Providers, payers, and manufacturers operate in an environment shaped by shifting regulatory priorities, expanding telehealth provision, and changing patient expectations for safety, convenience, and cost transparency. Consequently, understanding the dynamics that influence prescribing practices, adherence, and accessibility is essential for stakeholders who must balance clinical efficacy with supply chain and commercial realities.

In addition, the social and political context surrounding contraception influences demand patterns, formulary decisions, and public sector procurement strategies. Emerging digital health pathways are reshaping how patients access prescriptions and adhere to recommended regimens, while formulation innovation and lifecycle management of both branded and generic products are redefining competitive dynamics. Therefore, an actionable introduction to this landscape must acknowledge the interplay between clinical guidance, regulatory frameworks, and market channels, and set the stage for deeper analysis that follows in subsequent sections.

How digital health expansion, regulatory rebalancing, and formulation evolution are reshaping access, prescribing behavior, and supplier strategies in the oral contraceptive market

The oral contraceptive market is experiencing transformative shifts that are altering how products are developed, prescribed, distributed, and perceived by users. Advances in digital health have accelerated telemedicine consultations and online pharmacy fulfillment, enabling more rapid access to prescriptions while also introducing new compliance and verification challenges. At the same time, policy movements toward over-the-counter availability in some jurisdictions and expanded pharmacist prescribing authority in others are changing the traditional gatekeepers of access and prompting manufacturers to reconsider packaging, labeling, and patient support services.

Moreover, clinical and formulation trends are prompting differentiated product strategies. Patient-centric formulations and lower-hormone options are gaining attention as providers seek to balance efficacy with tolerability, and there is renewed focus on real-world adherence data to inform guideline updates and payer decisions. Parallel to these clinical shifts are supply-side transformations: contract manufacturing optimization, API sourcing diversification, and vertical integration strategies are being deployed to mitigate disruptions. Finally, increased competition from generic manufacturers and a heightened emphasis on value-based procurement are driving innovation in patient support programs, digital adherence tools, and evidence generation to sustain brand differentiation.

Analyzing how recent United States tariff measures are prompting supply chain realignment, sourcing diversification, and procurement strategy adjustments across the oral contraceptive ecosystem

Recent trade policy measures introduced in the United States have created a cumulative impact across multiple facets of the oral contraceptive supply chain. Increased import tariffs and heightened scrutiny of upstream suppliers can alter the cost calculus for active pharmaceutical ingredient procurement and finished-dose manufacturing, prompting manufacturers to reevaluate sourcing strategies, manufacturing footprints, and inventory policies. As a result, companies are increasingly considering nearshoring, dual-sourcing, and long-term supplier contracts to reduce exposure to tariff volatility and ensure continuity of supply.

At the clinical procurement level, hospitals, clinics, and pharmacies are responding to these shifts by reassessing purchasing agreements and inventory buffers. Transitional effects include renegotiation of tender terms and closer collaboration between procurement and regulatory affairs teams to anticipate customs clearance complexities. In response to potential cost pressures, some manufacturers are enhancing operational efficiency through process improvements and scale consolidation, while others pursue strategic partnerships to secure critical intermediates. Importantly, these structural adjustments are unfolding alongside policy and judicial reviews that may change the long-term tariff landscape, so stakeholders should plan for both immediate operational contingencies and sustained strategic realignments.

In-depth segmentation intelligence linking product type, formulation nuances, dosage strategies, brand positioning, and distribution channels to competitive and operational priorities

Key segmentation insights reveal how product characteristics, formulation design, dosing strategies, brand positioning, and channel structures interact to determine competitive opportunity and risk. Based on Product Type, the market distinctions between combined oral contraceptives and progestin-only pills drive differences in prescribing patterns, tolerability profiles, and target patient cohorts, which in turn influence marketing, medical education, and formulary approaches. Based on Formulation, the differences among biphasic, monophasic, and triphasic designs affect bleeding patterns, cycle control expectations, and the messaging required for clinician and patient education.

Furthermore, based on Dosage Strength, the strategic differentiation between high dose and low dose pills has implications for adverse event profiles, adherence considerations, and patient preference segmentation. Based on Brand, the tension between branded and generic offerings shapes lifecycle management, reimbursement strategies, and investment in patient support or real-world evidence generation. Finally, based on Distribution Channel, the structure that encompasses hospital pharmacy, online platforms, and retail pharmacy-with the hospital pharmacy further studied across private hospital and public hospital environments-determines procurement models, reimbursement flows, inventory practices, and the configuration of patient access programs. Integrating these segmentation lenses enables more precise commercial planning, tailored messaging for clinicians and patients, and alignment of manufacturing volumes with channel-led demand.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory priorities, distribution pathways, and manufacturing choices

Regional dynamics create distinct strategic imperatives for stakeholders operating across different geographic clusters. In the Americas, regulatory frameworks, payer mixes, and telehealth adoption rates influence the balance between retail pharmacy, hospital procurement, and online distribution, driving specific go-to-market models and reimbursement considerations. In contrast, the Europe, Middle East & Africa grouping exhibits wide heterogeneity in regulatory requirements and healthcare infrastructure, which necessitates adaptive licensing strategies, differentiated clinical evidence packages, and tailored distribution partnerships that reflect local procurement norms and public-sector procurement cycles.

Meanwhile, the Asia-Pacific region presents a diverse set of market conditions where rapid digital adoption intersects with variable regulatory timelines and manufacturing capabilities. In many jurisdictions within this region, strong local manufacturing ecosystems and evolving intellectual property enforcement standards affect decisions about local production versus export orientation. Taken together, these regional variations require companies to deploy nuanced market-entry strategies, prioritize regulatory and commercial investments by country or cluster, and synchronize supply chain and distribution models with regional payer and provider behaviors.

Competitive intelligence revealing how formulation innovation, supply resilience, strategic partnerships, and lifecycle management define leadership in the oral contraceptive category

Competitive dynamics among companies active in the oral contraceptive category are defined by a combination of innovation in formulations, supply chain resilience, commercial execution, and the ability to demonstrate differentiated value to clinicians and payers. Leading strategic approaches include investing in patient-centric information and adherence services, securing long-term supply agreements for key intermediates, and prioritizing regulatory pathways that accelerate market access. In addition, lifecycle management tactics such as incremental formulation changes, packaging redesigns, and expanded indications are commonly used to extend product relevance and maintain prescriber loyalty.

Partnerships and alliances, including those with contract manufacturers, digital health platforms, and specialty distributors, are increasingly central to delivering end-to-end solutions that address both clinical adherence and convenience. Meanwhile, companies focusing on generic entry leverage scale manufacturing and cost optimization to compete on price, while larger innovators may emphasize clinical evidence, patient support infrastructure, and brand trust to preserve premium positioning. Across these strategies, firms that align R&D priorities with real-world outcomes and that coordinate effectively across regulatory, supply chain, and commercial functions are better positioned to navigate evolving policy and distribution landscapes.

Actionable strategic priorities for industry leaders to synchronize evidence generation, sourcing resilience, digital engagement, and stakeholder advocacy for sustained market advantage

Industry leaders should adopt a multi-dimensional strategy that harmonizes clinical evidence generation, supply chain flexibility, and channel-specific commercialization to sustain competitive advantage. First, integrating robust real-world adherence studies and post-marketing surveillance into product portfolios will strengthen payer negotiations and inform clinical messaging. Second, diversifying API and finished-dose manufacturing through qualified dual sourcing and selective nearshoring will reduce exposure to trade policy shifts and logistical disruptions while maintaining cost competitiveness.

Moreover, companies should accelerate their digital engagement strategies by embedding telehealth-compatible prescribing support, personalized adherence tools, and seamless e-commerce fulfillment to meet growing patient expectations. Concurrently, active engagement with policymakers, payers, and professional societies will help shape favorable prescribing frameworks and pharmacist scope-of-practice expansions. Finally, leaders should consider targeted investments in brand-differentiating services such as nurse-led counseling, patient education platforms, and value-based contracting pilots to demonstrate outcomes and foster long-term trust with prescribers and patients.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and clinical literature synthesis, and cross-validated scenario analysis to underpin actionable conclusions

The research underpinning this analysis relies on a combination of qualitative and quantitative approaches designed to validate trends, triangulate perspectives, and identify practical implications for decision makers. Primary research included structured interviews with clinicians, procurement officers, pharmacy directors, and industry executives to capture firsthand insights on prescribing behaviors, procurement strategies, and distribution challenges. Secondary research drew on regulatory filings, clinical guideline updates, policy announcements, and open-source literature to contextualize shifts in access and formulation preferences.

Data synthesis employed a cross-validation framework that reconciled stakeholder interviews with documented regulatory changes and supply chain developments, while scenario analysis was used to explore the implications of policy and trade variations. Limitations of the methodology include the inherent lag between policy announcements and observable market responses, and the variability of clinical and procurement practices across jurisdictions. Nonetheless, the combined methodological approach provides a robust foundation for strategic recommendations, and the findings were further reviewed by domain experts to ensure relevance and practical applicability.

Concluding synthesis that connects regulatory change, supply resilience, formulation innovation, and patient-centric delivery as the core drivers of future success in the category

In summary, the oral contraceptive landscape is at an inflection point where regulatory shifts, digital access pathways, and supply chain dynamics converge to reshape how products are developed, delivered, and used. Stakeholders who proactively align clinical evidence generation with adaptive sourcing strategies and channel-specific commercialization will be better equipped to meet evolving patient needs and mitigate risk. Transitional policy measures and trade developments underscore the importance of agile procurement and long-term supplier relationships, while formulation differentiation and patient support services offer clear avenues for competitive advantage.

Looking ahead, sustained success will depend on the ability to integrate cross-functional insights into coherent strategies that address both near-term operational challenges and longer-term clinical and market trends. By prioritizing resilience, evidence, and patient-centric delivery models, organizations can navigate uncertainty and harness emerging opportunities to improve access and outcomes for patients who rely on oral contraceptive pills.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increased adoption of progestin-only oral contraceptive pills among breastfeeding and postpartum mothers
• 5.2. Growing preference for low-dose combined oral contraceptives to minimize side effects and enhance adherence
• 5.3. Surge in demand for oral contraceptives with clinically proven non-contraceptive health benefits
• 5.4. Expanding telehealth service integration for online prescription and home delivery of contraceptive pills
• 5.5. Rising popularity of 24/4 and extended-cycle pill regimens offering fewer hormone-free intervals
• 5.6. Emergence of digital fertility-tracking apps paired with oral contraceptives for personalized cycle management
• 5.7. Increasing market penetration of generic oral contraceptives following patent expirations of leading brands
• 5.8. Shifts in consumer preference toward eco-friendly packaging and sustainable sourcing of contraceptive pills

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Contraceptive Pills Market, by Product Type

• 8.1. Combined Oral Contraceptives
• 8.2. Progestin-Only Pills

9. Oral Contraceptive Pills Market, by Formulation

• 9.1. Biphasic
• 9.2. Monophasic
• 9.3. Triphasic

10. Oral Contraceptive Pills Market, by Dosage Strength

• 10.1. High Dose
• 10.2. Low Dose

11. Oral Contraceptive Pills Market, by Brand

• 11.1. Branded
• 11.2. Generic

12. Oral Contraceptive Pills Market, by Distribution Channel

• 12.1. Hospital Pharmacy
  • 12.1.1. Private Hospital
  • 12.1.2. Public Hospital
• 12.2. Online Platforms
• 12.3. Retail Pharmacy

13. Oral Contraceptive Pills Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Oral Contraceptive Pills Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Oral Contraceptive Pills Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Bayer AG
  • 16.3.2. Teva Pharmaceutical Industries Ltd.
  • 16.3.3. Pfizer Inc.
  • 16.3.4. Merck & Co., Inc.
  • 16.3.5. Viatris Inc.
  • 16.3.6. Sun Pharmaceutical Industries Ltd.
  • 16.3.7. Gedeon Richter Plc
  • 16.3.8. Lupin Limited
  • 16.3.9. Dr. Reddy's Laboratories Ltd.
  • 16.3.10. Sandoz International GmbH

LIST OF FIGURES

• FIGURE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. ORAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. ORAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ORAL CONTRACEPTIVE PILLS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 105. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 107. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 109. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 111. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 113. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 115. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 120. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 121. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 122. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 123. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 124. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 125. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 126. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 128. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 130. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 131. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 134. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 135. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 136. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 137. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 138. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 139. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 140. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 141. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 142. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 144. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 173. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 176. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 177. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 178. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 179. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 180. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 181. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 182. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 183. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 184. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 186. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 187. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 190. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 191. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 192. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 193. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 194. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 195. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 196. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 197. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 198. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 199. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 200. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 201. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 204. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 205. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 206. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 207. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 208. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 209. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 210. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 211. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 212. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 213. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 214. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 222. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 223. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 224. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 225. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 226. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 227. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 231. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 234. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 235. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 236. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 237. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 238. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 239. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 240. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 241. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 242. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 243. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 244. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 245. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 249. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 250. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 251. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 252. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 253. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 254. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 255. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 256. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 259. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 264. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 265. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 266. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 267. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 268. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 269. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 270. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 271. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 272. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 273. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 274. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 275. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 276. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 277. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 278. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 279. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 280. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 281. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 282. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 283. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 284. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 285. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 286. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 287. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 288. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 289. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 290. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 291. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 292. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 293. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 294. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 295. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 296. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 297. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 298. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 299. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 300. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 301. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 302. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 303. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 304. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 305. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 306. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 307. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 308. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 309. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
• TABLE 310. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
• TABLE 311. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 312. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 313. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 314. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 315. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 316. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 317. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 318. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 319. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
• TABLE 320. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
• TABLE 321. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)

T